Patents-Review.com
ClassID:

97173 ⎘

C07K16/2821 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102

Recent Application in this class:
#1
20260098858
2026-04-09

Fc-Engineered Monoclonal Antibodies Refractory to Tumor Immunosuppressive ICAM-1/CD54

 #2
20250288611
2025-09-18

ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT

 #3
20250276018
2025-09-04

CAR CONSTRUCTS AND METHODS OF TREATMENT

 #4
20240417474
2024-12-19

ANTIBODY DERIVED FROM CANCER SURVIVOR, AND USE THEREOF

 #5
20240307548
2024-09-19

ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES

 #6
20240287188
2024-08-29

Antibody specifically binding to ICAM-1 and use thereof

 #7
20240218030
2024-07-04

MUTATED FERRITIN PROTEIN

 #8
20240189445
2024-06-13

Targeted Therapeutic Lipid Nanoparticles and Methods of Use

 #9
20240148888
2024-05-09

INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF

 #10
20240076399
2024-03-07

ENGINEERED ANTIBODIES AND USES THEREOF

 #11
20230312740
2023-10-05

HUMANIZED CD38 AND ICAM1 ANTIBODIES AND USES THEREOF

 #12
20230285462
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #13
20230285461
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #14
20230285460
2023-09-14

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #15
20230272108
2023-08-31

Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto

 #16
20230263830
2023-08-24

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #17
20230241115
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #18
20230241114
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #19
20230241113
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #20
20230241112
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #21
20230241110
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #22
20230241109
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #23
20230241108
2023-08-03

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #24
20230233612
2023-07-27

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

 #25
20230212295
2023-07-06

Methods of treatment by targeting VCAM1 and MAEA

 #26
20230190931
2023-06-22

Anti-TIGIT Antibodies

 #27
20230181731
2023-06-15

Anti-TIGIT Antibodies

 #28
20220280653
2022-09-08

INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF

 #29
20220002429
2022-01-06

TUMOR CELL AGGREGATION INHIBITORS' FOR TREATING CANCER

 #30
20220000922
2022-01-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #31
20210401892
2021-12-30

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #32
20210347881
2021-11-11

INHIBITION OF KIDNEY DISEASE RELAPSE BY TARGETED CYTOKINE DEPLETION

 #33
20210338839
2021-11-04

COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY

 #34
20210338735
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #35
20210338734
2021-11-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #36
20210332139
2021-10-28

MODULATION OF LEUKOCYTE ACTIVITY IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE

 #37
20210330708
2021-10-28

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #38
20210260120
2021-08-26

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #39
20210244765
2021-08-12

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #40
20210213064
2021-07-15

Peptides and combination of peptides of non- canonical origin for use in immunotherapy against different types of cancers

 #41
20210145888
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #42
20210145887
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #43
20210145886
2021-05-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #44
20210137986
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #45
20210137985
2021-05-13

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #46
20210113619
2021-04-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #47
20210100845
2021-04-08

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #48
20210095045
2021-04-01

Methods of treatment by targeting VCAM1 and MAEA

 #49
20210069251
2021-03-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #50
20210060078
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #51
20210060077
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #52
20210060074
2021-03-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #53
20210052654
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #54
20210052653
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #55
20210052652
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #56
20210052651
2021-02-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #57
20200360433
2020-11-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #58
20200323919
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #59
20200323918
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #60
20200323916
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #61
20200323915
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #62
20200323914
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #63
20200323913
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #64
20200323911
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #65
20200323910
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #66
20200323909
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #67
20200323907
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #68
20200323906
2020-10-15

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #69
20200306311
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #70
20200306308
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #71
20200306305
2020-10-01

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #72
20200297772
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #73
20200297771
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #74
20200297770
2020-09-24

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #75
20200268800
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #76
20200268799
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #77
20200268798
2020-08-27

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #78
20200261506
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #79
20200261505
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #80
20200261504
2020-08-20

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #81
20200222465
2020-07-16

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #82
20200206268
2020-07-02

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #83
20200197441
2020-06-25

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #84
20200179454
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #85
20200179453
2020-06-11

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #86
20200174011
2020-06-04

ANTIGEN RECEPTOR SCREENING ASSAY

 #87
20200171091
2020-06-04

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #88
20200163996
2020-05-28

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #89
20200155605
2020-05-21

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #90
20200155604
2020-05-21

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #91
20200108097
2020-04-09

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #92
20200093862
2020-03-26

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #93
20200085972
2020-03-19

Engineered liposomes as cancer-targeted therapeutics

 #94
20200085874
2020-03-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #95
20200085873
2020-03-19

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #96
20200038448
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #97
20200038447
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #98
20200038446
2020-02-06

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #99
20190330365
2019-10-31

Engineered antibodies and uses thereof

 #100
20190315867
2019-10-17

Anti-TIGIT antibodies

 #101
20190255164
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #102
20190255113
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #103
20190255112
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #104
20190255110
2019-08-22

Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

 #105
20190100591
2019-04-04

Anti-TIGIT antibodies

 #106
20190092862
2019-03-28

Multispecific fab fusion proteins and use thereof

 #107
20190077878
2019-03-14

METHODS FOR TREATING CANCER BY TARGETING VCAM1 AND MAEA

 #108
20180298088
2018-10-18

COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY

 #109
20180221482
2018-08-09

USE OF ANTIBODIES AGAINST ICAM-1 IN COMBINATION WITH AN ANTI CANCER DRUG IN THE TREATMENT OF PATIENTS

 #110
20180072809
2018-03-15

Oncolytic adenoviruses coding for bi-specific antibodies

 #111
20180022808
2018-01-25

ANTIBODY CONSTRUCT

 #112
20170362325
2017-12-21

USE OF BLOCKING-REAGENTS FOR REDUCING UNSPECIFIC T CELL-ACTIVATION

 #113
20170362320
2017-12-21

Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)

 #114
20170253657
2017-09-07

MODULATION OF LEUKOCYTE ACTIVITY IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE

 #115
20170073402
2017-03-16

COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY

 #116
20160280788
2016-09-29

USE OF ANTIBODIES AGAINST ICAM-1 IN THE TREATMENT OF PATIENTS WITH RELAPSED CANCER

 #117
20160238613
2016-08-18

ANTIGEN RECEPTOR SCREENING ASSAY

 #118
20160237167
2016-08-18

COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY

 #119
20160220702
2016-08-04

Compositions and methods for treatment of diabetic retinopathy

 #120
20160206764
2016-07-21

Monoclonal antibody and derivatives

 #121
20160130357
2016-05-12

Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same

 #122
20160041173
2016-02-11

Methods and arrays for use in the same

 #123
20150252111
2015-09-10

Antibody that binds domain 2 of ICAM-1 and methods of treatment

 #124
20150132368
2015-05-14

Targeted protein replacement for the treatment of lysosomal storage disorders

 #125
20140314793
2014-10-23

Biological materials and uses thereof

 #126
20140314666
2014-10-23

Targeted carriers for drug delivery across the gastrointestinal epithelium

 #127
20140242072
2014-08-28

ANTI-ICAM-1 ANTIBODIES TO TREAT MULTIPLE-MYELOMA RELATED DISORDERS

 #128
20140154259
2014-06-05

Method for the treatment of inflammatory disorders

 #129
20140148583
2014-05-29

Antibody that binds domain 2 of ICAM-1 and methods of treatment

 #130
20140147382
2014-05-29

IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS

 #131
20130336886
2013-12-19

Tumor specific antibodies and uses therefor

 #132
20130323819
2013-12-05

Expression of antibody or a fragment thereof in lactobacillus

 #133
20130243768
2013-09-19

MULTIMERIC PROTEINS AND METHODS OF MAKING AND USING SAME

 #134
20130230539
2013-09-05

Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy

 #135
20130195940
2013-08-01

METHOD TO INHIBIT RECRUITMENT OF MONOCYTES AND MACROPHAGES BY AN ICAM-3 INHIBITOR

 #136
20130164307
2013-06-27

USE OF CAMELID-DERIVED VARIABLE HEAVY CHAIN VARIABLE REGIONS (VHH) TARGETING HUMAN CD18 AND ICAM-1 AS A MICROBICIDE TO PREVENT HIV-1 TRANSMISSION

 #137
20130142811
2013-06-06

Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof

 #138
20130064763
2013-03-14

Anti-ICAM-1 single domain antibody and uses thereof

 #139
20120328706
2012-12-27

Polymer particle delivery compositions and methods of use

 #140
20120328632
2012-12-27

INHIBITION OF LEUKOCYTE ADHESION

 #141
20120321557
2012-12-20

ANTI-ICAM3 ANTIBODY AND USE THEREOF

 #142
20120263652
2012-10-18

Targeted carriers for drug delivery across the gastrointestinal epithelium

 #143
20120121599
2012-05-17

COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY

 #144
20120087925
2012-04-12

Method for the treatment of inflammatory disorders

 #145
20120087916
2012-04-12

ANTI-ICAM-1 ANTIBODY, USES AND METHODS

 #146
20120083589
2012-04-05

Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof

 #147
20120076730
2012-03-29

Peptides for transport of therapeutics and their carriers in mouse models and humans

 #148
20110262461
2011-10-27

Biological materials and uses thereof

 #149
20110123442
2011-05-26

Tumor specific antibodies and uses therefor

 #150
20110045060
2011-02-24

KIT FOR DETECTING CANCER CELLS METASTASIZING INTO SENTINEL LYMPH NODE

 #151
20110044976
2011-02-24

Humanized antibodies

 #152
20100203061
2010-08-12

PREVENTION AND TREATMENT OF RETINAL ISCHEMIA AND EDEMA

 #153
20100168394
2010-07-01

Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof

 #154
20100098714
2010-04-22

Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy

 #155
20100055115
2010-03-04

COMPOSITIONS AND METHODS FOR STEM CELL DELIVERY

 #156
20100036103
2010-02-11

Method for producing apoprotein

 #157
20090324598
2009-12-31

Method for the treatment of inflammatory disorders

 #158
20090317404
2009-12-24

REDUCTION AND PREVENTION OF CELL-ASSOCIATED HIV TRANSEPITHELIAL MIGRATION, MICROBIDES AND OTHER FORMULATIONS AND METHODS

 #159
20090302806
2009-12-10

CONTROL CIRCUITRY FOR PROVIDING AN INTERFACE BETWEEN CONNECTABLE TERMINAL AND PERIPHERAL DEVICE CIRCUITRY

 #160
20090285752
2009-11-19

IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS

 #161
20090274689
2009-11-05

Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke

 #162
20090226430
2009-09-10

RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

 #163
20090221036
2009-09-03

RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY

 #164
20090202511
2009-08-13

Targeted protein replacement for the treatment of lysosomal storage disorders

 #165
20090155176
2009-06-18

Compositions and methods for treatment of diabetic retinopathy

 #166
20090087427
2009-04-02

ICAM-1 binding antibodies

 #167
20090035321
2009-02-05

Intercellular adhesion molecules and their binding ligands

 #168
20090035257
2009-02-05

Devices, compositions and methods for the protection and repair of cells and tissues

 #169
20080299121
2008-12-04

Multivalent recombinant antibodies for treating HRV infections

 #170
20080241143
2008-10-02

Inhibition of leukocyte adhesion

 #171
20080057054
2008-03-06

Modulation of Phagocytosis in Neurons

 #172
20080025992
2008-01-31

Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy

 #173
20080025913
2008-01-31

Novel Anti-Dc-Sign Antibodies

 #174
20080019977
2008-01-24

Prevention and treatment of retinal ischemia and edema

 #175
20070110733
2007-05-17

Compositions and methods for stem cell delivery

 #176
20070071742
2007-03-29

Humanized antibodies

 #177
20060194318
2006-08-31

Cultured cd14+ antigen presenting cells

 #178
20060177416
2006-08-10

Polymer particle delivery compositions and methods of use

 #179
20060013818
2006-01-19

Method of treating granuloma annulare or sarcoid

 #180
20050255108
2005-11-17

Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke

 #181
20050226877
2005-10-13

Method for the treatment of inflammatory disorders

 #182
20050214942
2005-09-29

Activation and expansion of cells

 #183
20050186264
2005-08-25

Targeting drug/gene carriers to irradiated tissue

 #184
20050176020
2005-08-11

I-CAM related protein

 #185
20050153447
2005-07-14

Activation and expansion of cells

 #186
20050107585
2005-05-19

Signal-1/signal-2 bifunctional peptide inhibitors

 #187
20050070461
2005-03-31

Means and methods for altering the motility of the gastrointestinal tract